Tumor Aggressiveness In Biliary Tract Cancer: New Molecular Markers
Main Category: GastroIntestinal / GastroenterologyAlso Included In: Cancer / Oncology
Article Date: 27 Aug 2009 - 4:00 PDT
| Patient / Public: | ![]() |
4 (2 votes) |
| Healthcare Prof: | ![]() |
3 (2 votes) |
Despite recent advances in diagnosis and treatment, the prognosis of patients with biliary tract cancer is still poor. Elucidating the biological characteristics of these carcinomas has become necessary to improve the prognosis of patients and to devise better treatment strategies. A recent study report that invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in the progression of biliary tract cancer.
The potential role of LN5 and MMP7 in human cancer is receiving increasing attention. However, expression of LN5 and MMP7 in biliary tract cancer has not been clearly addressed. A research article published in the World Journal of Gastroenterology addresses this question. The research team led by Dr. Hiroyuki Yamamoto of Sapporo Medical University systematically analyzed the expression of LN5 chains and MMP7 in biliary tract cancer.
Using RT-PCR, real-time RT-PCR, immunohistochemistry, casein zymography, and cell invasion assays, the research team analyzed the expression and role of LN5 and MMP7 in biliary tract cancer, in relation to clinicopathological characteristics. Invasive front dominant expression of LNγ2 and LNβ3 was associated with tumor progression. Active MMP7 detected by casein zymography was correlated with depth of invasion and advanced stage. Down-regulation of MMP7 expression by siRNA resulted in a significant decrease in biliary tract cancer cell invasion in vitro.
In the view of Professor Hiroyuki Yamamoto, detection of LNγ2, LNβ3, and active MMP7 could be molecular markers for tumor aggressiveness in biliary tract cancer. Understanding how LNγ2, LNβ3, and active MMP7 are induced and how their expression is blocked may represent a future strategy for therapeutic intervention in the treatment of patients with biliary tract cancer.
Overexpression of LN5 chains, especially LNγ2, and MMP7 has been reported in various types of carcinomas, such as hepatocellular, colorectal, stomach, and esophagus. LN5 chains and MMP7 could be future therapeutic targets in clinical settings.
This research was performed by doctors from the First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Reference:
Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Yasushi Adachi Y, Imai K, Shinomura Y. Overexpression of beta-3 and gamma 2 chains of laminin 5 and MMP7 in the progression of biliary tract cancer. World J Gastroenterol 2009; 15(31):3865-3873 http://www.wjgnet.com/1007-9327/15/3865.asp
Source:
Lin Tian
World Journal of Gastroenterology
Visit our gastrointestinal / gastroenterology section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/162066.php>
APA
http://www.medicalnewstoday.com/releases/162066.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





